2021
DOI: 10.1016/j.chom.2020.11.013
|View full text |Cite
|
Sign up to set email alerts
|

The immune landscape in tuberculosis reveals populations linked to disease and latency

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

18
126
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1
1

Relationship

1
7

Authors

Journals

citations
Cited by 138 publications
(166 citation statements)
references
References 64 publications
18
126
2
Order By: Relevance
“…In-depth and unbiased pro ling of pulmonary immune cell populations led us to discover that CXCL9/10 expression in pulmonary macrophages is enhanced upon coinfection but not after type I IFN receptor blockade, which was also validated with multiplex immuno uorescence analysis and ELISA. Consistent with our ndings, Esaulova et al also suggested that both type I and II IFN signals accumulate in pulmonary active disease, but they could not identify the events thereafter 70 . In comparison, we further tracked the next events after increased CXCL9/10 expression.…”
Section: Discussionsupporting
confidence: 83%
See 1 more Smart Citation
“…In-depth and unbiased pro ling of pulmonary immune cell populations led us to discover that CXCL9/10 expression in pulmonary macrophages is enhanced upon coinfection but not after type I IFN receptor blockade, which was also validated with multiplex immuno uorescence analysis and ELISA. Consistent with our ndings, Esaulova et al also suggested that both type I and II IFN signals accumulate in pulmonary active disease, but they could not identify the events thereafter 70 . In comparison, we further tracked the next events after increased CXCL9/10 expression.…”
Section: Discussionsupporting
confidence: 83%
“…Indeed, Cai et al performed scRNA-seq using human PBMCs from healthy controls and individuals with latent or active tuberculosis 69 . Additionally, Esaulova et al recently described the immune landscape of TB latency and disease in the lungs of nonhuman primates, de ning the features of pulmonary active TB, such as the accumulation of IFN producers and responders in the lung 70 . Here, single-cell analysis played a key role in providing clues to discover the mechanism by which viral infection disrupts immune responses and exacerbates Mtb-mediated pathology.…”
Section: Discussionmentioning
confidence: 99%
“…IFNγ-expressing NK cells have been described to accumulate in the pleural fluid of patients with TB pleurisy [112]. Individuals with LTBI exhibited increased numbers of circulating NK cells in peripheral blood and these cells exhibited increased cytotoxic capacity associated with high expression of granzyme B and perforin [113], and accumulation of CD27 + NK cells in the lung has also been associated with LTBI in nonhuman primates [114]. In contrast, circulating NK cells were markedly decreased in peripheral blood of patients with active TB [113].…”
Section: Epithelial Barriers and Innate Immunitymentioning
confidence: 99%
“…Conversely, TBM patients displayed a higher amount of cytotoxic CD56 dim CD16 + NK cells in the circulation. Cytotoxicity mediated by NK cells is protective for some neurological complications of infections [ 51 , 52 ], and increased numbers of cytotoxic NK cells in the lung are a hallmark that defines latency over active disease in macaques infected with Mtb [ 28 ]. Thus, the increased abundance of CD56 dim CD16 + NK cells in TBM patients' blood might reflect an active mobilization of these cells to the CNS as an attempt to control the local infection.…”
Section: Discussionmentioning
confidence: 99%
“…Several phenotypical and functional deficiencies are displayed by peripheral NK cells from PTB patients compared to LTBI individuals, supporting a role for NK cells in defenses against pulmonary Mtb [ 15 , 20 24 ]. Strikingly, NK cell subsets with adaptive properties expand in mice, primates, and humans with TB, making them potential targets for vaccines [ 25 28 ]. However, the phenotype and function of NK cells in TB patients that develop extrapulmonary disease manifestations, including TBM, has not been extensively addressed.…”
Section: Introductionmentioning
confidence: 99%